海外の治験の状況「1」での検索結果
379件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Effects of oral Levosimendan on breathing function in patients with the disease Amyotrophic Lateral Sclerosis (ALS)
- Amyotrophic lateral sclerosis (ALS) br>MedDRA version: 20.0 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Australia, Austria, Belgium, Canada, Finland, Germany, Ireland, Italy, Netherlands, Spain, Sweden, United Kingdom, United States
- 2018-02-28
Authorised
- A study to evaluate the effect of Cinryze® (C1 esterase inhibitor [human]) for the treatment of acute antibody-mediated rejection in kidney transplant patients
- Acute Antibody Mediated Rejection (AMR) in kidney transplant patients MedDRA version: 20.0 Level: PT Classification code 10023439 Term: Kidney transplant rejection System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Body processes [G] - Immune system processes [G12]
- Canada, France, Germany, Netherlands, Spain, United States
- 2015-11-13
Authorised
- Study to Evaluate Imetelstat (JNJ-63935937) in Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS).
- Myelodysplastic syndrome (MDS) MedDRA version: 18.0 Level: HLT Classification code 10028536 Term: Myelodysplastic syndromes System Organ Class: 100000004851 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Belgium, France, Germany, Italy, Korea, Republic of, Mexico, Netherlands, Russian Federation, Spain, Switzerland, United Kingdom, United States
- 2015-09-04
Authorised
- Study of REGN1979 (anti-CD20 and anti- CD3) and REGN2810 (anti-PD-1) in Patients with a Specific Type of Blood Cancer
- B-cell malignancies MedDRA version: 20.0 Level: PT Classification code 10003903 Term: B-cell lymphoma refractory System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10003917 Term: B-cell type acute leukaemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10026945 Term: Mature B-cell type acute leukaemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10067184 Term: Burkitt's leukaemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10003890 Term: B precursor type acute leukaemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10020267 Term: Hodgkin's disease refractory System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10020266 Term: Hodgkin's disease recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10003902 Term: B-cell lymphoma recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Germany, Spain, United States
- 2015-06-30
Authorised
- A long term extension trial of BI 655066 in patients with moderately to severely active Crohn's disease
- Crohn's disease MedDRA version: 18.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Canada, Germany, Korea, Republic of, Spain, United States
- 2015-06-18
Authorised
- The First-in-Human Study of an Investigational Drug, ALN-AAT, in Healthy Subjects and Patients with ZZ Type Alpha 1 Antitrypsin Deficiency Liver Disease
- ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease MedDRA version: 19.1 Level: PT Classification code 10001806 Term: Alpha-1 anti-trypsin deficiency System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- United Kingdom, United States
- 2015-05-15
Authorised
- HIV-1 Attachment Inhibitor comparison in Heavily Treatment Experienced patients
- HIV, Adult MedDRA version: 17.1 Level: PT Classification code 10020161 Term: HIV infection System Organ Class: 10021881 - Infections and infestations ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Argentina, Australia, Belgium, Brazil, Canada, Chile, Colombia, Denmark, France, Germany, Greece, Ireland, Italy, Mexico, Netherlands, Norway, Peru, Poland, Portugal, Puerto Rico, Romania, Russian Federation, South Africa, Spain, Taiwan, United Kingdom, United States
- 2015-02-19
Authorised
- Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease (CALM)
- Crohn's disease MedDRA version: 17.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Austria, Belgium, Czech Republic, France, Germany, Hungary, Italy, Netherlands, Spain, Sweden, United Kingdom, United States
- 2010-07-19
Authorised
- Phase 1/2a study to evaluate the safety, activity, and pharmacokinetics of escalating doses of GNS561 in patients with primary liver cancers
- Hepatocellular carcinoma Intrahepatic cholangiocarcinoma MedDRA version: 20.0 Level: LLT Classification code 10019828 Term: Hepatocellular carcinoma non-resectable System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10077738 Term: Hepatocellular carcinoma metastatic System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10073077 Term: Intrahepatic cholangiocarcinoma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Belgium, United States
- 2017-10-06
Authorised
- Extension Study to Evaluate the Long-Term Administration of ALN-GO1 in Patients with Primary Hyperoxaluria Type 1
- Primary Hyperoxaluria Type 1 (PH1) MedDRA version: 20.0 Level: PT Classification code 10020703 Term: Hyperoxaluria System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- France, Germany, Israel, Jordan, Netherlands, United Arab Emirates, United Kingdom, United States
- 2017-07-11
